Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Aromatase inhibitor
Ki67
Primary breast cancer
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
12 04 2023
12 04 2023
Historique:
received:
02
12
2022
accepted:
27
02
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
epublish
Résumé
Ki67 assessed at diagnosis (Ki67 In POETIC 4480 postmenopausal patients with primary ER and/or PgR + breast cancer were randomised 2:1 to 2 weeks' presurgical AI (anastrozole or letrozole) or no presurgical treatment (control). Ki67 was measured centrally in core-cut biopsies taken prior to AI and in core-cuts or the excision biopsy at surgery. Relationships between the Ki67 and biologic factors were explored using linear regression. Established associations of Ki67 The magnitude of this study allowed characterisation of relationships between Ki67
Identifiants
pubmed: 37046348
doi: 10.1186/s13058-023-01626-3
pii: 10.1186/s13058-023-01626-3
pmc: PMC10099675
doi:
Substances chimiques
Aromatase Inhibitors
0
Ki-67 Antigen
0
Letrozole
7LKK855W8I
Receptor, ErbB-2
EC 2.7.10.1
Receptors, Progesterone
0
MKI67 protein, human
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39Informations de copyright
© 2023. The Author(s).
Références
NPJ Breast Cancer. 2016 May 18;2:16014
pubmed: 28721378
BMC Cancer. 2011 Aug 07;11:341
pubmed: 21819622
Eur J Cancer. 2003 Nov;39(16):2318-27
pubmed: 14556923
BMC Cancer. 2016 Sep 22;16(1):745
pubmed: 27658825
Ann Oncol. 2011 Oct;22(10):2201-7
pubmed: 21335417
Lancet. 2002 Jun 22;359(9324):2131-9
pubmed: 12090977
J Clin Oncol. 2022 Aug 10;40(23):2557-2567
pubmed: 35404683
J Clin Pathol. 2010 Sep;63(9):800-4
pubmed: 20671052
J Clin Oncol. 2011 Apr 20;29(12):1531-8
pubmed: 21422407
Nat Commun. 2016 Nov 09;7:13294
pubmed: 27827358
J Clin Oncol. 2017 Apr 1;35(10):1061-1069
pubmed: 28045625
J Clin Oncol. 2011 Jun 10;29(17):2342-9
pubmed: 21555689
Lancet Oncol. 2020 Nov;21(11):1443-1454
pubmed: 33152284
J Clin Oncol. 2006 Jul 1;24(19):3019-25
pubmed: 16754938
J Natl Cancer Inst. 2011 Nov 16;103(22):1656-64
pubmed: 21960707
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
Mod Pathol. 2022 Oct;35(10):1362-1369
pubmed: 35729220
J Clin Oncol. 2005 Oct 1;23(28):7212-20
pubmed: 16192605
Cancer Res. 2001 Dec 1;61(23):8452-8
pubmed: 11731427
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
J Clin Oncol. 2005 Apr 10;23(11):2477-92
pubmed: 15767642
J Natl Cancer Inst. 2007 Jan 17;99(2):167-70
pubmed: 17228000
J Natl Cancer Inst Monogr. 2011;2011(43):120-3
pubmed: 22043057
EBioMedicine. 2022 Sep;83:104205
pubmed: 35985932
J Clin Oncol. 2008 Mar 1;26(7):1059-65
pubmed: 18227529
J Clin Oncol. 2017 Apr 1;35(10):1041-1048
pubmed: 28113032
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):951s-8s
pubmed: 15701892